EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in Cholangiocarcinoma

• Andreas-Claudius Hoffmann ,

  Contributed equally to this work with: Andreas-Claudius Hoffmann, Eray Goekkurt

  * E-mail: ach@o117.com

  Affiliation Department of Medical Oncology, West German Cancer Center, University Duisburg-Essen, Essen, Germany

  ⨯
• Eray Goekkurt ,

  Contributed equally to this work with: Andreas-Claudius Hoffmann, Eray Goekkurt

  Affiliation Department of Oncology, Hematology and Stem Cell Transplantation, University Hospital Aachen, RWTH University Aachen, Aachen, Germany

  ⨯
• Peter V. Danenberg,

  Affiliation Department of Biochemistry and Molecular Biology, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States of America

  ⨯
• Sylvia Lehmann,

  Affiliation Internal Medicine Clinic I, Carl Gustav Carus University Hospital, Dresden, Germany

  ⨯
• Gerhard Ehninger,

  Affiliation Internal Medicine Clinic I, Carl Gustav Carus University Hospital, Dresden, Germany

  ⨯
• Daniela E. Aust,

  Affiliation Institute of Pathology, Carl Gustav Carus University Hospital, Dresden, Germany

  ⨯
• Jan Stoehlmacher-Williams

  Affiliation Internal Medicine Clinic I, Carl Gustav Carus University Hospital, Dresden, Germany

  ⨯